Corpus Intelligence IC Memo — KFH - ANTIOCH 2026-04-26 15:54 UTC
IC Memo — KFH - ANTIOCH
Investment Committee Memorandum | CA | 144 beds | Grade B | EBITDA uplift $32.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

KFH - ANTIOCH

CCN 050760 | CONTRA COSTA, CA | 144 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

KFH - ANTIOCH is a 144-bed suburban community hospital in CONTRA COSTA, CA with $445.4M in net patient revenue and a 8.1% operating margin. The hospital serves a payer mix of 6.5% Medicare, 7.9% Medicaid, and 85.6% commercial.

Thesis: Turnaround. Our ML models identify $32.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 8.1% to 15.4% (+736bps).

Net Revenue HCRIS$445.4M
Current EBITDA COMPUTED$35.9M
Operating Margin COMPUTED8.1%
Occupancy HCRIS67.8%
Revenue / Bed COMPUTED$3.1M
Net-to-Gross HCRIS27.1%
Distress Probability ML41.1%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
200
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of 8.1% places it above the state median. Among 200 size-comparable peers (72-288 beds), the median margin is -3.9%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (72-288), prioritizing same-state peers. 200 hospitals in the comp set.

HospitalStateBedsRevenueMargin
KFH - ANTIOCH (Target)CA144$445.4M8.1%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%
CALIFORNIA PACIFIC MEDICAL CENCA274$987.8M-18.5%
ZUCKERBERG SAN FRANCISCO GENERCA284$889.5M-41.7%
SANTA MONICA UCLA MEDICAL CENTCA281$835.9M2.8%
ENLOE MEDICAL CENTERCA258$834.4M-0.5%
KFH - SOUTH SACRAMENTOCA233$803.9M5.9%
COMMUNITY HOSP. MONTEREY PENINCA227$797.2M9.3%
KFH - MANTECACA213$796.8M15.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $32.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$9.4M+210bp18mo
Cost to Collect4.5%2.5%$8.9M+200bp12mo
Denial Rate Reduction12.0%6.5%$8.8M+198bp12mo
A/R Days Reduction5200.0%3800.0%$5.4M+122bp9mo
Clean Claim Rate88.0%96.0%$285K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$9.4M
Cost to Collect
$8.9M
Denial Rate Reduction
$8.8M
A/R Days Reduction
$5.4M
Clean Claim Rate
$285K
Total EBITDA Uplift$32.8M
Current EBITDA$35.9M
+ RCM Uplift+$32.8M
Pro Forma EBITDA$68.7M
Current Margin8.1%
Pro Forma Margin15.4%
WC Released (1x)$17.1M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$55.2M$564.7M10.22x59.2%
Base (11x exit)10.0x11.0x$55.2M$639.2M11.57x63.2%
Bull Case9.0x11.0x$49.7M$765.3M15.39x72.8%
Bull (12x exit)9.0x12.0x$49.7M$849.6M17.09x76.4%
Bear Case11.0x10.0x$60.8M$382.9M6.30x44.5%
Bear (11x exit)11.0x11.0x$60.8M$440.9M7.26x48.6%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 200 hospitals with 72-288 beds
  • Same-state prioritization (n=201)
  • Comp margins: P25=-17.9% / P50=-3.9% / P75=4.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.